Moreover, the greater stability of the Cagri-induced bypass conformation relative to the rAmy-induced bypass conformation, when engaged with the CTR, is likely a major contributor to the increased conformational stability of the Cagri-AMY 2 R-Gs complex relative to the rAmy-AMY 2 R-Gs complex
After first use (first needle puncture), the vial should be used within 28 days
doi: 10.1530/EJE-09-0622 101 AtisGDalkilincAAltuntasYAtisAGurbuzCOfluogluYet al
Yoon J, Hyun M-H, Yang J-P, Park M-J, Park S
If approved, CagriSema would provide patients and healthcare professionals with an additional treatment option supported by results from the REDEFINE clinical program, including robust efficacy, high treatment completion rates, and a tolerability profile consistent with its underlying pharmacology. 1 Safety and Tolerability Across REDEFINE 1 and REDEFINE 2, safety findings aligned with the established profile of the GLP-1 receptor agonist class